Under the agreement, EVQLV will generate and provide therapeutic antibody designs against multiple therapeutic targets selected by Ono, using EVQLV's proprietary Artificial Intelligence (AI)-powered Antibody Design Engine. Based on the antibody designs generated through the collaboration, Ono will generate potential antibodies to create, develop and commercialize antibody drug candidates. During the research period, Ono will pay EVQLV research funding and success-based research milestone payments. Ono will retain option rights to exclusively and globally develop and commercialize the antibody drug candidates.
'We have been actively working to create biologics including antibody drugs in order to address unmet medical needs for a wide range of diseases. We are very pleased to collaborate with EVQLV having its proprietary AI-powered Antibody Design Engine. We expect that the EVQLV's AI-technology will enable us to create novel antibody candidates against multiple targets more promptly and effectively,' said Dr.
'Ono has a successful history of identifying unique targets that have translated into life-changing medicines that have helped countless patients around the world,' said
About EVQLV, INC
EVQLV transforms antibody development for biotechs and pharmaceutical companies using artificial intelligence. EVQLV's AI-powered Antibody Design Engine uses a wide range of machine learning and software engineering techniques to generate fully-human and developable therapeutic antibody designs.
About EVQLV's AI-powered antibody design platform
EVQLV's antibody design platform combines evolution, structure, and protein language models to generate target-specific antibody sequences. The platform designs and modifies antibodies while retaining conformational and functional integrity, providing a shorter path to recombinant antibody expression and functional testing. By combining antibody discovery and engineering into a single workflow, EVQLV's end-to-end design platform can perform de novo design, biobetter design, and affinity maturation, all while enhancing developability and specificity.
Contact:
Email: customerinfo@ono-pharma.com
(C) 2023 Electronic News Publishing, source